Derma Sciences CEO Highlights Rapid Growth of MEDIHONEY Products in Presentation at Comvita Annual M

Derma Sciences CEO Highlights Rapid Growth of MEDIHONEY Products in Presentation at Comvita Annual Meeting

PRINCETON, N.J.--(BUSINESS WIRE)-- Derma Sciences, Inc. (NAS: DSCI) , a medical device and pharmaceutical company focused on advanced wound care, announces that its chief executive officer, Edward J. Quilty, highlighted the rapid growth of MEDIHONY® Dressings with medical grade Manuka (Leptospermum) Honey, and the rewarding relationship between Derma Sciences and Comvita Limited in a presentation at Comvita's annual shareholders' meeting in New Zealand yesterday. MEDIHONEY is the leading brand of medical grade honey products and is one of the fastest-growing moist wound healing wound dressings in the field of advanced wound care, with a sales growth rate exceeding 30% annually.

Brett Hewlett, chief executive officer of Comvita, said, "The growth of MEDIHONEY products has been exceptional and we are delighted with the work Derma Sciences has done to establish MEDIHONEY as a powerhouse brand in wound healing. Together with Derma Sciences we will look for ways to vertically integrate to control quality and cost by modernizing the harvesting and acquiring new Apiaries, in order to continue to meet the anticipated demand of Derma Sciences' customer base."

"Our partnership with Comvita is strong and mutually beneficial," said Mr. Quilty. "Under the MEDIHONEY brand we have developed five distinct product lines that are directed to the care of wounds with differing severity and characteristics. Behind the strength of the MEDIHONEY line, we fully expect to achieve our guidance of sales growth of our advanced wound care portfolio of between 30% and 40% this year. MEDIHONEY is an anchor product in our advanced wound care portfolio and was the basis for embarking on the expansion of our U.S.-based direct sales force last year. We look forward to continued success with MEDIHONEY and with Comvita," Mr. Quilty concluded.

Comvita is the world's largest processor of Manuka Honey providing more than 60 percent of the world's supply." "It owns 16,000 hives specialist Manuka Honey apiaries and maintains a high-technology medical honey extraction facility and has in place Manuka planting and land development programs, plant breeding and agronomics programs. In February 2010 Derma Sciences licensed exclusive worldwide rights from Comvita for the MEDIHONEY professional wound and skin care products. Current MEDIHONEY products includeMEDIHONEY Calcium Alginate Dressing, MEDIHONEYPaste, MEDIHONEY Gel, MEDIHONEY HCS and MEDIHONEY Honeycolloid™.

About Derma Sciences, Inc.

Derma Sciences is a medical technology company focused on three segments of the wound care marketplace: pharmaceutical wound care products; advanced wound care dressings to address chronic wounds including diabetic ulcers; and traditional dressings. The Company has begun its Phase 3 clinical trial in diabetic foot ulcer healing with DSC127, based on excellent Phase 2 data. Its MEDIHONEY® product is the leading brand of honey-based dressings for the management of wounds and burns. The product has been shown in clinical studies to be effective in a variety of indications. TCC-EZ® is its gold-standard total contact casting system for diabetic foot ulcers. Other novel products introduced into the $14 billion global wound care market include XTRASORB® for better management of wound exudate, and BIOGUARD® for infection prevention.

For more information please visit www.dermasciences.com.

Forward-Looking Statements

Statements contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate" or "continue" are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release or that are otherwise made by or on behalf of the Company. Factors that may affect the Company's results include, but are not limited to, product demand, market acceptance, impact of competitive products and prices, product development, completion of an acquisition, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include but are not limited to, those discussed in the Company's filings with the U.S. Securities and Exchange Commission.

Derma Sciences, Inc.
Barry Wolfenson, 609-514-4744
Group President, Advanced Wound Care and Pharmaceutical Development
bwolfenson@dermasciences.com
or
LHA
Kim Sutton Golodetz, 212-838-3777
kgolodetz@lhai.com
or
Bruce Voss, 310-691-7100
bvoss@lhai.com

KEYWORDS: United States North America New Jersey

INDUSTRY KEYWORDS:

The article Derma Sciences CEO Highlights Rapid Growth of MEDIHONEY Products in Presentation at Comvita Annual Meeting originally appeared on Fool.com.

Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.